Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage

Ian R. Logan¹, Hesta V. McNeill¹, Susan Cook¹, Xiaohong Lu¹, David W. Meek², Frances V. Fuller-Pace³, John Lunec¹ and Craig N. Robson¹,*

¹Northern Institute for Cancer Research, Newcastle University, Paul O’Gorman Building, Medical School, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK, ²Molecular Signalling Group and ³Cancer Biology Group, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK

Received 17 November 2008; Revised and Accepted 4 March 2009

ABSTRACT

Here we define an important role for heat shock factor 1 (HSF1) in the cellular response to genotoxic agents. We demonstrate for the first time that HSF1 can complex with nuclear p53 and that both proteins are co-operatively recruited to p53-responsive genes such as p21. Analysis of natural and synthetic cis elements demonstrates that HSF1 can enhance p53-mediated transcription, whilst depletion of HSF1 reduces the expression of p53-responsive transcripts. We find that HSF1 is required for optimal p21 expression and p53-mediated cell-cycle arrest in response to genotoxins while loss of HSF1 attenuates apoptosis in response to these agents.

To explain these novel properties of HSF1 we show that HSF1 can complex with DNA damage kinases ATR and Chk1 to effect p53 phosphorylation in response to DNA damage. Our data reveal HSF1 as a key transcriptional regulator in response to genotoxic compounds widely used in the clinical setting, and suggest that HSF1 will contribute to the efficacy of these agents.

INTRODUCTION

Functioning as a transcription factor p53, in response to various stresses including DNA damage, can control the expression of genes involved in cell-cycle arrest, apoptosis and DNA repair (1). For example, the cyclin-dependent kinase inhibitor p21Waf1/Cip1 is an important mediator of p53-dependent cell-cycle arrest (2,3), BH3-only members of the Bcl-2 family such as Noxa and PUMA are central to p53-mediated apoptosis (4,5) and gadd45 is involved in DNA repair (6). Over 50% of tumors carry inactivating mutations in the TP53 gene encoding p53 (7).

Over 50% of tumors carry inactivating mutations in the TP53 gene encoding p53 (7). Other tumors may harbor aberrations that indirectly disrupt p53. For example excessive MDM2 activity which can result from gene amplification (found in 7% of solid tumors) could be a principal mechanism of p53 inactivation (9). MDM2 is an E3 ubiquitin ligase that interacts with the p53 N-terminus leading to p53 polyubiquitination and proteosomal destruction under normal conditions (10). Following genotoxic stress p53 can be phosphorylated on serine residues 15 and 20 (11,12) leading to MDM2 dissociation, thereby stabilizing p53 and releasing its transcriptional activity. Additional phosphorylation of multiple p53 residues (13) combined with C-terminal acetylation (14) enhances p53 transcriptional activities leading to upregulation of genes such as gadd45, p21 and PUMA. Recently, small molecule antagonists have been developed that can overcome the repressive effects of MDM2 on p53 thereby activating p53 in a non-genotoxic manner (15–18) and increasing the prospect of being able to reactivate p53 in tumors. For example, the MDM2 antagonist nutlin-3, is particularly effective in causing p53-dependent apoptosis and exhibits antitumor activity on human xenografts in nude mice (16,19,20).

Many different classes of proteins have been described that can increase p53-mediated transcription including p300/CBP (21), CARM1 (22), Set9 (23), JMY (24), ASPP (25), and more general transcription factors such as TBP, TAFs and Sp1 (26,27). Elegant in vitro work has demonstrated that posttranslational modification of histones by p53 coactivators is required for p53-mediated transcription from chromatin templates (22), while p53 itself is also a substrate for posttranslational modifications by coactivators such as p300 and Set9 (14,23). To add further complexity, new and unexpected p53-binding proteins are still being discovered that can influence the transcriptional activity of p53 (28–30). Our understanding of exactly how p53 uses these cofactors remains incomplete.

Heat shock factor 1 (HSF1) belongs to a family of four conserved transcription factors although only HSF1, HSF2 and HSF4 are characterized in humans (31).
Upon activation by various types of stress including heat shock, osmotic imbalance and geldanamycin treatment (32,33), HSF1 is thought to prime and bind to heat shock response elements (HSEs) present in heat shock gene promoters, such as that of heat shock chaperone 70 (HSP70), which are composed of multiple adjacent and inverse copies of the pentanucleotide motif 5'-nGAAn-3' (34). HSF1 is capable of increasing the transcriptional rate of target genes via a carboxy-terminal transactivation domain (35,36) and interaction with transcriptional co-regulators such as CHIP and Daxx (37,38), whereas interaction with the HSP70 chaperone inhibits HSF1 transcriptional activity through negative feedback (39). Various studies indicate that HSF1, and its associated factors such as CHIP and HSP70, protect cells from thermal stress and point towards a prosurvival role for the HSF1 pathway in response to hyperthermia (37,40,41). Specifically, mice lacking HSF1 fail to elicit heat shock protein expression in response to heat shock and do not acquire thermotolerance in response to sublethal doses of hyperthermia, resulting in accelerated heat shock-induced apoptosis (42). Drosophila harboring HSF mutants also fail to acquire thermotolerance (43). Interestingly, a recent study has shown that whilst loss of HSF1 in p53-deficient mice lead to suppression of lymphomas, the incidence of other tumors such as sarcomas and testicular tumors was increased (44). Additionally, loss of HSF1 contributed to genomic instability suggesting some overlap between p53 and HSF1 functions. Paradoxically, another study has shown some dependency on HSF1 for survival (45). For some time, p53 has been known to interact with some members of the HSF1 pathway including HSP70 and HSP90 (46,47) and HSP90 has been shown to play an important role in p53 transcriptional activities (48).

Here we describe a novel interaction between HSF1 and the tumor suppressor p53 that is enhanced upon DNA damage. We show that HSF1 is important for p53 function in cell-cycle arrest and apoptosis. These new HSF1 activities do not involve previously described properties of HSF1 in response to heat shock, such as increased chaperone expression, HSF1 phosphorylation and cellular relocalization.

**MATERIALS AND METHODS**

**Cell culture and flow cytometry**

Cell lines were maintained in RPMI 1640 as described (49). Doxorubicin, etoposide and actinomycin D and doxycycline were all from Sigma. For cell-cycle analysis cells were resuspended in PBS containing 2% FCS then permeabilized with 1% Triton-X-100 (Sigma), treated with 100 µg/ml RNase (Sigma) and stained with 500 µg/ml propidium iodide (Sigma) before analysis on a BD FACScan instrument. For active Caspase 3 measurements FITC-conjugated active caspase-3 antibody was used as recommended (BD Pharmingen) and annexin V was purchased from Sigma.

**Immunoprecipitation, expression vectors and reporter gene assays, immunoblotting and protein purification**

Immunoprecipitation was performed using cell extracts as described (49), with 1µg of indicated antibody. Recovered material was analyzed by immunoblotting. For reporter gene assays the indicated reporter vectors were co-transfected with 50 ng of constitutively expressed β-galactosidase reporter gene and p53 or HSF1 in pcDNA3 (a gift from Richard Voellmy), where indicated, using Superfect (Qiagen). Post treatment, cell extracts were used in luciferase (Promega) and β-galactosidase reporter assays (50). Luciferase activities were calibrated to β-galactosidase values. For immunoblotting the following antibodies were used; p21 Ab-1, p53 Ab-6 (Oncogene research products), TBP Ab818 (Abcam), HSF1 Ab-1 (Neomarkers) or HSF1 SPA-901 (Stressgen), phospho p53 #9919 (Cell Signaling). GST-tagged p53 proteins were expressed in BL21 cells and purified according to standard procedures.

**Chromatin immunoprecipitation (ChIP) and DNA-binding assay**

ChIP was performed essentially as described (51), with minor modifications. Before immunoprecipitation, DNA concentrations from soluble chromatin fractions were quantified using a Nanodrop spectrophotometer. Fifty micrograms of this material were used per immunoprecipitation with specific antibodies against p53 (Ab-6, Oncogene research products) or HSF1 (Stressgen). Post-ChIP material and input samples were subject to quantitative PCR using an Applied Biosystems 7900 system with oligonucleotides GGATCTGTGGTAGGTGAGGGTCA GG and GGATCTGTGGTAGGTGAGGGTCA GG and GGATCTGTGGTAGGTGAGGGTCA GG to amplify the gadd45 p53 response element (22), GGA GTGGAGTTCAGGAGGAGGTCA GG and GGATCTGTGGTAGGTGAGGGTCA GG to amplify the gadd45 p53 response element (22), GGA GTGGAGTTCAGGAGGAGGTCA GG and GGATCTGTGGTAGGTGAGGGTCA GG to amplify the gadd45 p53 response element of p21 (3). TransAM transcription factor assay (Active Motif) was used to measure p53-binding activity to a consensus sequence 5'GGACATGCAGGGCAAGCC3' immobilized onto a 96 well plate. Assays were performed as recommended.

**RNAi**

siRNAs against target sequences HSF1 GAGAAAGATC CCCCTGATGdTdT and p53 GACTCCAGTGTAAT CTACdTdT were as described (52) and control (ns) siRNA was as described (51). Used at a final concentration of 5–20 nM, these were transfected with HiPerFect (Qiagen) according to manufacturers’ protocols.

**Proliferation assays**

WST1 reagent (Roche) was used as described by the manufacturer to measure end point proliferation on cells seeded in 96-well plates. Six replicates were used per condition.
Quantitative RT–PCR

Measurements of PCNA and PUMA transcript levels were performed using Taqman products (Applied Biosystems). p21, gadd45 and GAPDH transcript levels were measured using SYBR Green as described (51) with oligonucleotide sequences GTGTTAGAAACTCTG TACGCTCGGT and GACCTCAAGGTCGAAAA CGG for p21; CCAAAACTATGGCTGCACACT and CCATGCGAGAAAGAAACTATG for gadd45 and C GACCACTTTGTCAGCTCA and GGGTCTTACTC CTTGGAGGC for GAPDH, respectively. Dissociation curves confirmed PCR product specificity. Transcript quantities were corrected to values for GAPDH.

RESULTS

HSF1 interacts with p53 during genotoxic stress

Given the potential link between p53 and HSF1 (44) we first investigated whether p53 and HSF1 might form protein–protein interactions. Human 293T cells that harbor high levels of wild-type p53 due to stabilization by SV40 DNA tumor virus large T antigen were initially examined. Immunoprecipitation of endogenous HSF1 with polyclonal HSF1 antibody resulted in specific co-immunoprecipitation of endogenous p53 suggesting the proteins can complex in cells (Figure 1A). In a reciprocal experiment, immunoprecipitation of endogenous p53 resulted in specific co-immunoprecipitation of endogenous HSF1 (Figure 1B). Additionally, immunoprecipitation using HSF1 antibody recovered p53 from wild-type MEFs, but not HSF1–/– MEFs (Figure 1C). Finally, co-immunoprecipitation of endogenous p53 resulted in specific co-immunoprecipitation of endogenous HSF1 suggesting that p53–HSF1 interactions are modulated by genotoxic stress but not by heat shock. In order to delineate the region on p53 that interacts with HSF1, we next assessed the ability of HSF1 to interact with p53 deletion mutants in a GST pull-down assay. HSF1 could interact with full-length p53 as well as residues 1–292, but not an N-terminal deletion mutant lacking residues 1–248 (Supplementary Figure 2). Additionally, HSF1 retained interactions with a proline-rich domain deletion mutant but did not interact with residues 1-42 that contain the p53 transactivation domain (Supplementary Figure 2). This suggests that the region on p53 that interacts with HSF1 lies between residues 42–248, which includes the DNA-binding domain of p53. We were unable to more finely delineate a single interaction site on p53; further experiments suggested that HSF1–p53 interactions might be multiple and complex. It is unknown how much HSF1 is interacting with p53 in these experiments.

We next wanted to examine whether HSF1 might be activated by DNA damaging agents in a similar manner to heat shock. Previous studies have demonstrated that HSF1 can undergo phosphorylation in response to hyperthermia which correlates with HSF1 accumulation in nuclear bodies and increased HSF1 target gene expression (31,53–55) and references therein. We assessed the nuclear:cytoplasmic ratio of HSF1 in response to doxorubicin or heat shock. In untreated U2OS cells HSF1 was not an N-terminal deletion mutant lacking residues 1–248 but did not interact with residues 1–292, but interacted with full-length p53 in a GST pull-down assay. HSF1 could interact with full-length p53 as well as residues 1–292, but did not interact with residues 1–42 that contain the p53 transactivation domain (Supplementary Figure 2). This suggests that the region on p53 that interacts with HSF1 lies between residues 42–248, which includes the DNA-binding domain of p53. We were unable to more finely delineate a single interaction site on p53; further experiments suggested that HSF1–p53 interactions might be multiple and complex. It is unknown how much HSF1 is interacting with p53 in these experiments.

We next wanted to examine whether HSF1 might be activated by DNA damaging agents in a similar manner to heat shock. Previous studies have demonstrated that HSF1 can undergo phosphorylation in response to hyperthermia which correlates with HSF1 accumulation in nuclear bodies and increased HSF1 target gene expression (31,53–55) and references therein. We assessed the nuclear:cytoplasmic ratio of HSF1 in response to doxorubicin or heat shock. In untreated U2OS cells HSF1 was present in both nuclear and cytoplasmic fractions and little evidence of HSF1 hyperphosphorylation was present (Figure 1F). As expected HSF1 hyperphosphorylation,

![Figure 1.](https://example.com/figure1.png)
HSF1 regulates p53-mediated transcription

Previous studies have shown that HSF1 can upregulate pro-survival genes in response to heat shock whereas p53 can regulate pro-apoptotic genes in response to genotoxic stress. However, no study has examined HSF1-mediated transcription in response to genotoxic stress. Given that p53 and HSF1 interact in a manner that can be influenced by genotoxic stress we specifically examined what role HSF1 might play in p53-regulated transcription.

First, to get an overview of whether HSF1 is involved in expression of p53 target genes, we depleted cells of HSF1 by means of RNAi then measured steady state levels of p53 target gene transcripts. Specific siRNA targeted towards HSF1 was used and cells transfected with p53 or non-silencing siRNAs served as controls. Depletion of p53 resulted in dramatic loss of p21 transcript expression as measured by quantitative RT–PCR (Figure 2A) as well as a blunted response to chemotherapy; we cannot completely rule out this alternative mechanism, as even small changes in HSP transcript and/or protein levels may play a role in p53 activation.

HSF1 regulates p53-mediated transcription

Previous studies have shown that HSF1 can upregulate pro-survival genes in response to heat shock whereas p53 can regulate pro-apoptotic genes in response to genotoxic stress. However, no study has examined HSF1-mediated transcription in response to genotoxic stress. Given that p53 and HSF1 interact in a manner that can be influenced by genotoxic stress we specifically examined what role HSF1 might play in p53-regulated transcription.

First, to get an overview of whether HSF1 is involved in expression of p53 target genes, we depleted cells of HSF1 by means of RNAi then measured steady state levels of p53 target gene transcripts. Specific siRNA targeted towards HSF1 was used and cells transfected with p53 or non-silencing siRNAs served as controls. Depletion of p53 resulted in dramatic loss of p21 transcript expression as measured by quantitative RT–PCR. Depletion of HSF1 also produced a striking decrease in p21 expression (Figure 2A) as well as a blunted response to chemotherapy; we cannot completely rule out this alternative mechanism, as even small changes in HSP transcript and/or protein levels may play a role in p53 activation.
silencing p300 also produced some reduction in p21 transcript levels (Figure 2B).

To ascertain whether these effects could be detected at the protein level the expression of p21 protein was measured in extracts produced from cells transfected with the siRNAs. Depletion of HSF1 substantially reduced both steady-state levels of p21 and induction of p21 protein expression mediated by doxorubicin, without affecting p53 protein levels (Figure 2C). Similarly, p53 depletion partly abrogated the induction of p21 protein (Figure 2C). These data suggest that HSF1 is important for expression of p21 in response to chemotherapy. To validate this suggestion we examined p21 expression in MEFs that lack HSF1. In response to doxorubicin wild-type MEFs expressed a readily detectable amounts of p21 protein yet HSF1–/– MEFs did not (Figure 2D).

We wanted to delineate whether HSF1 could alter the expression of p53 targets by modulating p53 transcriptional activities or by affecting these genes via some other mechanism. To do this we firstly studied p53 cis-regulatory elements. Two reporter genes were initially used that contain either consensus p53-binding sequences (termed PG13) or mutated, non-functional, sequence (termed MG15). These reporter genes were transfected into a p53-deficient background of HCT116 p53−/− cells. As expected, co-transfection of increasing amounts of exogenous p53 resulted in increases in PG13 reporter gene activity, but no increase in MG15 reporter gene activity (Supplementary Figure 4) and 1 ng of exogenous p53 was sufficient to enhance PG13 2.5-fold. Interestingly, co-transfection of increasing amounts of HSF1 further enhanced p53-induced reporter gene activity (Figure 3A). This enhancement by HSF1 was not observed in the absence of co-transfected p53 (Figure 3A). Additionally, treatment with 0.5 μM doxorubicin led to increases in reporter gene activity, which could be further enhanced by co-transfection of HSF1 (Figure 3A). As expected, p300 transfection also produced some increase in reporter gene expression (Figure 3A). No significant changes in reporter activity were observed with the MG15 reporter gene either in the presence of p53 and HSF1 (Figure 3A) or doxorubicin (data not shown). These observations suggest that HSF1 overexpression can increase p53 transcriptional activity and that mutation of the p53-binding sequence is sufficient to abrogate the effects of HSF1 on p53-binding cis elements. We next assessed whether depletion of HSF1 would result in reduced p53 reporter gene expression. U2OS cells that harbor wild-type p53 were transfected with siRNA targeting either p53 or HSF1 or luciferase as an internal control, whereas non-silencing (ns) siRNA was used as a negative control. Additionally, cells were treated for 12 h with genotoxic agents to further induce reporter gene activity before harvesting. As expected, p53 or luciferase silencing followed by transfection of the PG13 or p21 reporter genes resulted in large reductions in reporter gene activity compared to control transfectants (Figure 3B). HSF1 silencing also resulted in a striking reduction in reporter gene activity in either untreated or genotoxic treated cells (Figure 3B).

Having shown an effect of HSF1 on p53 target gene expression and transfected reporter genes containing isolated p53 response elements, we next examined recruitment of HSF1 and p53 to natural gene promoters by quantitative ChIP. This would enable us to determine whether HSF1 is recruited to the promoter regions of native p53 target genes, thus affecting p53-dependent expression at the transcriptional level. As shown previously, treatment of cells with genotoxins resulted in increased recruitment of p53 to the p21 and gadd45 promoter (2,22,56). Interestingly, HSF1 recruitment to the p21 and gadd45 promoters could also be detected under basal conditions, which underwent a large increase in response to doxorubicin, actinomycin D or etoposide (Figure 4A and Supplementary Figure 5). To confirm specificity, we tested recruitment of p53 or HSF1 to a non-specific region of the gadd45 gene, 2 kb downstream from the gadd45 promoter. Only background levels of binding were found at this region, which did not show significant enrichment upon genotoxin treatment of cells (Figure 4A) suggesting that HSF1 and p53 binding to the p53 response elements was specific in our assay. Additionally, ChIP with irrelevant antibody (irr) recovered only background levels of DNA (Figure 4A). Next, we wanted to assess the
dependency of HSF1 and p53 on each other for their recruitment to p53 target gene promoters. Comparison of isogenic p53-proficient (HCT116+/+) and p53-deficient (HCT116−/−) cell lines showed that while a low level of HSF1 could be recruited to the p21 promoter in the absence of p53, drug induced increases in HSF1 binding occurred only in p53-proficient cells (Figure 4B). We also examined the interdependency of p53 and HSF1 for recruitment to the p21 and gadd45 promoters using siRNA (Figure 4C). Congruent with the data from HCT116 cells, p53 knockdown substantially reduced HSF1 binding to either of the endogenous p53 response elements within the p21 or gadd45 promoters in U2OS cells treated with doxorubicin (Figure 4C and Supplementary Figure 6). Conversely, HSF1 knockdown also resulted in a large reduction of p53 recruitment to the gadd45 or p21 p53 response elements (Figure 4C). We additionally examined the efficiency of p53 binding to a consensus DNA sequence by ELISA. First, p53 from wild-type MEF nuclear extracts showed a 6.7-fold increase in DNA binding in response to doxorubicin, whereas no increase was observed in HSF1−/− MEFs (Figure 4D). Secondly, HSF1 or p53 siRNA-mediated knockdown in U2OS cells produced a striking reduction in p53 DNA-binding activity (Figure 4D) in response to doxorubicin.

**HSF1 is involved in p53-mediated growth regulation**

p53 can induce cell-cycle arrest and apoptosis in a manner dependent upon its competence as a transcription factor and murine HSF1 has previously been shown to be required for heat shock-mediated G2/M arrest (57). Having observed some dependency for HSF1 in p53-mediated transcriptional regulation we next assessed the contribution HSF1 might have to p53-mediated growth arrest.

We firstly assessed the effects of genotoxic compounds on MEF cell cycle. Strikingly, etoposide and doxorubicin could invoke a dramatic G2/M checkpoint cell-cycle arrest in wild-type MEFs but not in HSF1−/− MEFs (Figure 5A). We next wanted to examine if human HSF1 would act similarly in cancer cells. First, U2OS cells were treated with the same compounds and showed a G2/M arrest, as expected (Figure 5B). Intriguingly, p53 or HSF1 depletion blunted this response to genotoxic stress; cells did not arrest as readily as judged by diminished increases in G2/M checkpoint populations in response to etoposide or doxorubicin (Figure 5C). In order to examine whether this effect was dependent upon p53, we next analyzed p53 deficient and proficient cells. In response to doxorubicin HCT116+/+ p53 proficient cells transfected with non-silencing siRNA demonstrated a G2/M arrest, however HSF1 knockdown completely abrogated this effect (Figure 5D). In agreement with previous studies (2,58) HCT116+/− p53 deficient cells were still capable of efficient G2/M arrest in response to doxorubicin. Strikingly, HSF1 siRNA transfection did not affect G2/M arrest in HCT116+/− p53 deficient cells (Figure 5D). This suggests that HSF1-mediated cell-cycle arrest in response to doxorubicin is p53-dependent. In order to examine the impact of HSF1 on cellular proliferation we compared MEFs...
lacking HSF1 to wild-type MEFs. The concentration of doxorubicin required to produce a 50% decrease in proliferation in wild-type MEFs was approximately 250 nM, compared to 5 µM in HSF1–/– cells (Figure 5E). Wild-type MEFs were also more sensitive to etoposide and actinomycin D than HSF1+/+ MEFs (Figure 5E and data not shown).

To specifically study p53-mediated growth arrest and to be certain that HSF1 was required for p53-mediated changes in cell growth we utilized an alternative system. Rather than employ additional p53-activating drugs, that might have secondary effects on cells, we used SAOS2 osteosarcoma cells stably transfected with a doxycycline-inducible p53 vector (59), termed SAOS-tetWTp53 cells. First, we established that addition of 0.1 µg/ml doxycycline was sufficient to produce a 50% decrease in proliferation of SAOS-tetWTp53 cells (data not shown). Next we assessed the contribution of HSF1 to this growth arrest. Although very high transfection frequencies could not be achieved in these cells, transfection of p53 siRNA inhibited the reduction in proliferation from 53% to 70% and HSF1 depletion had the same effect (Figure 6A). We also examined apoptosis and found that addition of 0.1 µg/ml doxycycline to SAOS-tetWTp53 cells produced an 11-fold increase in apoptotic cell numbers from to 5% to 55% (Figure 6B), measured by flow cytometry using the active caspase-3 marker. Inspection of cell morphology also revealed widespread membrane blebbing upon p53 induction (data not shown). Depletion of HSF1 or p53 partly diminished this response resulting in fewer apoptotic cells after doxycycline treatment (Figure 6B). These data indicate that loss of HSF1 can specifically interfere with p53-induced growth arrest and apoptosis. Lastly, we compared apoptosis in MEFs lacking HSF1 to wild-type MEFs using annexinV staining and flow cytometry. In response to etoposide we measured ~90% of wild-type MEFs to be annexinV positive compared to 55% in HSF1–/– cells (Figure 6C). Addition of actinomycin D produced 80% annexinV positive wild type MEFs compared to 30% in HSF1–/– cells (Figure 6C).

**HSF1 interacts with DNA damage kinases and facilitates p53 phosphorylation**

Finally, in order to delineate a precise mechanism by which HSF1 might confer sensitivity to chemotherapy we examined post-translational modification on p53. Doxorubicin is well known to induce phosphorylation of multiple serine residues on p53 which are likely to contribute to its efficacy as a transcription factor (13). First, we examined the phosphorylation status of p53 in HSF1 immunoprecipitated material. Using phospho-specific p53 antibodies we found that p53 modified on serine 6 and serine 15 exhibited strong increases in HSF1 interaction in response to doxorubicin, whilst other modified forms of p53 such as serine 9 modified p53 did not interact as markedly upon DNA damage (Figure 7A). We next examined whether DNA damage kinases that are known to mediate the phosphorylation of p53 could complex with HSF1. Although we found no evidence of an interaction with ATM or DNA-PK (data not shown) we could
reproducibly co-immunoprecipitate HSF1 with Chk1 or ATR (Figure 7B and C), both of which are known to mediate phosphorylation of serine 6 and serine 15 on p53 (60). The HSF1–Chk1/ATR complex was not altered upon treatment with doxorubicin whilst HSF1–p53 interaction was only readily detectable in the presence of doxorubicin (Figure 7B). We next tested whether loss of HSF1...
might influence the phosphorylation of p53. HCT116 cells were transfected with HSF1 siRNA and treated with doxorubicin. Compared to control cells transfected with non-silencing siRNA we found that phosphorylation of serine 15 was reduced upon depletion of HSF1 (Figure 7D). Additionally, we tested MEFs lacking HSF1. Whilst both wild-type and HSF1+/- MEFs expressed p53 (Figure 2D) only in wild-type cells did p53 undergo phosphorylation on serine 15 (Figure 7E). Immunofluorescence using phospho-serine 15 also demonstrated a nuclear accumulation of serine 15 phosphorylation in wild-type MEFs which was absent in HSF1-/- MEFs (Supplementary Figure 7).

**DISCUSSION**

Here we define a novel role for HSF1 in the regulation of the tumor suppressor p53. We propose that HSF1 is required for the steady-state expression of a number of p53-responsive genes, but is also required for dynamic changes in expression of at least one critical p53 target gene, p21, on which HSF1 appears to function as an obligate p53 cofactor.

p53 can be activated by a wide variety of different signals such as DNA double strand breaks, inhibition of RNA production and pharmacological inhibition of MDM2. Yet, p53 is somehow able to co-ordinately regulate the expression of distinct subsets of genes depending upon the activating signal. Exactly how p53 is able to perform this remarkable function remains to be fully explained, although elegant studies have shown gene-specific mechanisms to exist such as the requirement for P-TEFb and RNA polII phosphorylation (61) and signal-specific recruitment of basal transcriptional machinery including TAFII250 and TFIIB to p53 target genes (62). Here, we found that different classes of compound that stabilize and activate p53 via distinct mechanisms require HSF1 in order to fully elicit their effects. Actinomycin D inhibits RNA polymerase I, thereby blocking ribosomal biogenesis and activating p53 through a non-classical pathway (61) that does not alter phosphorylation of N-terminal p53 serine residues (63). Doxorubicin and etoposide act in a different manner; by inhibiting topoisomerase activities thereby causing DNA double strand breaks which subsequently results in phosphorylation of p53 N-terminal p53 serine residues. However, in response to actinomycin D, doxorubicin or etoposide the interaction between HSF1 and p53 was increased suggesting that simply increasing the intracellular concentration of p53 may be sufficient to enable HSF1–p53 complex formation. We also demonstrate that induction of p21 gene expression and associated cell-cycle changes generated by these agents are dependent, at least in part, on HSF1. This could imply that HSF1 is a universal regulator of p53 function, independent of the p53 activating signal. In a recent study, downregulation of HSF1 in HeLa cells did not result in altered sensitivity to the chemotherapeutic genotoxin cisplatin (64). These cells are functionally deficient in p53 due to expression of the papillomavirus E6 protein. Our reporter gene assay and ChIP data from the HCT116-derived cell lines suggest that HSF1-mediated responses to chemotherapy are indeed dependent upon p53, which would explain the lack of altered drug sensitivity in HeLa cells.

Our ChIP studies, in keeping with other reports, showed that a basal level of p53 was present at the p21 promoter under non-stressed conditions but also that HSF1 was present under these conditions. This might provide a mechanism by which HSF1 and p53 can co-ordinately regulate inducible gene expression before further recruitment of the two factors in response to continued stress. Additionally, this would explain why HSF1 knockdown reduces p21 levels in unstressed cells. Strikingly, depletion of either HSF1 or p53 resulted in loss of recruitment of both factors to the p21 or gadd45 promoters suggesting that HSF1 and p53 are recruited co-operatively, in an interdependent manner. The mechanism by which HSF1 enhances p53 transcriptional activity could involve either increased recruitment of p53 to p53 response elements or activation/recruitment of additional factors such as HSPs that might facilitate p53 DNA binding. In keeping with the former model, our protein interaction data show that HSF1 binds near to, or in, the central DNA-binding domain of p53 which might facilitate p53–DNA interactions. However, we cannot dismiss the fact that HSF1 might also play an indirect role in p53 activation via HSPs which have previously been shown to be important for p53 folding, DNA binding and transcriptional activity (47,48).

In order to provide a more detailed mechanism by which HSF1 activates p53 we examined p53 phosphorylation in response to doxorubicin. p53 can be phosphorylated by multiple kinases including ATM (65,66), ATR (65,67), DNAPK (68) and CKII (69) on residues modified in response to DNA damage (11). HSF1 was required for phosphorylation of serine 15 on p53, but was not required for phosphorylation of other p53 serine residues. In some experiments we observed a reduction in serine 6 phosphorylation on p53 in response to HSF1 depletion however this was not always reproducible (data not shown). Our data show that HSF1 complexes with ATR and Chk1 which can phosphorylate p53 on residues 15 and 6 (60,70). Unlike the interaction with p53, the association of these kinases with HSF1 were not increased in response to doxorubicin. We therefore suggest that HSF1–Chk1–ATR form a steady-state complex that conditionally interacts with p53 in response to DNA damage to effect p53 phosphorylation (Figure 7F). We anticipate that there must also be other mechanisms by which HSF1 can activate p53 in response to signals such as actinomycin D which does not induce p53 phosphorylation. The indirect pathway referred to above, in which HSF1 could modulate HSP chaperone activities leading to p53 activation, is one putative mechanism.

Given previously published data derived from HSF1 deficient mice describing a pro-survival role for HSF1 in response to heat shock, we were surprised to discover that HSF1 can promote not only cell-cycle arrest but also p53-mediated apoptosis. Two recent studies have shown that HSF1 has a pro-apoptotic function, albeit in spermatogenesis. Transgenic mice expressing constitutively active
HSF1, either globally or restricted to spermatocytes, exhibit arrested spermatogenesis and abundant spermatocyte apoptosis, despite increased expression of HSPs (71,72). This effect was associated with increased levels of p53 and p53-responsive response genes of the Bcl-2 family (72) thereby providing another potential link between p53 and HSF1 pathways. Taken together with our data showing that HSF1 knockdown reduces PUMA levels this affords a transcriptional mechanism by which HSF1 could regulate p53-mediated apoptosis and suggests that a thorough assessment of the role of HSF1 in p53-mediated apoptosis should be undertaken. Intriguingly, HSF1 has recently been shown to be required for tumorigenesis in mice harboring activated oncogenes including RAS or p53R172H (45) which points towards a putative oncogenic role for HSF1. Notably however HSF1 overexpression alone was insufficient to promote cellular transformation; potent oncogene activation was also required (45). Although some of these results may seem difficult to reconcile with our data, the findings are not contradictory to ours because we have examined the role of HSF1 in response to DNA damage rather than oncogene activation. Taken together, the data show that in response to DNA damage in wild-type p53 cells, HSF1 promotes cell-cycle arrest and apoptosis whereas in cells containing powerful oncogenes HSF1 function is redirected to promote cell survival and tumorigenesis. Therefore, it would appear HSF1 can contribute to both pro- and anti-apoptotic pathways and what role HSF1 plays is dependent on the cellular context.

Since our data suggest that p53 and HSF1 have a common role in response to DNA damage, it would be useful to examine whether or not human cancers retain expression of wild-type HSF1 in the absence of p53 mutations. We speculate that mutations in HSF1 which inhibit the functions described herein would confer a growth advantage on tumor cells undergoing chemotherapy, a hypothesis yet to be explored. We have not yet investigated whether other members of the HSF family are capable of activating p53.

In summary, this study has uncovered a new role for HSF1 in the cellular response to stresses that activate p53. To define the precise mechanism(s) by which HSF1 can regulate p53-mediated transcription and apoptosis in response to multiple signals represents the next major challenge in understanding the complex functions of HSF1.

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS
HCT116-derived cell lines were provided by Bert Vogelstein. The p21-luciferase reporter gene was provided by Moshe Oren. Wild-type and mutant p53 reporter genes were supplied by Christine and Bohdan Wasylyk. Wild-type and HSF1−/− MEFs were kindly supplied by Ivor Benjamin.

FUNDING
Prostate Cancer Integral Management Approach (LSHC-CT-2004-504587); Prostate Cancer Mechanisms of Progression and Treatment (G010100/64424) and Foulkes Foundation Fellowship (to I.R.L.). Funding for open access charge: Medical Research Council, UK.

Conflict of interest statement. None declared.

REFERENCES


